Supplementary Material
Number of subjects reporting adverse events in the SAD study. The adverse events were coded by preferred term according to MEDRA coding. All the symptoms which could be considered potentially influenza like symptoms were reviewed by the authors, from the description provided by the investigator. From those, the chills reported by a subject in 30 μg dose group was the only one considered to be a potential case. The one instance of influenza-like illness reported in one subject in 0.15 μg dose group was observed approximately three months after receiving the single dose of AZD8848 and was discounted. Another instance of "feeling hot" reported 90 minutes after dosing in one subject in 15 μg dose group was a very localized symptom inside the mouth and was not considered to be an influenza like symptom by the authors. 
Rash papular 1 (6.3%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) Upper respiratory tract infection 1(6.3%) 1 (3.2%) 0 (0.0%) 1 (25.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) Urinary tract infection 1 (6.3%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) * The AZD8848 15 µg dose was repeated with same total dose but in a single inhalation rather than in multiple inhalations from the nebulizer as was the case in the prior 15 µg dose group. Target engagement was not significantly different from that seen after multiple inhalations (data not reported).
There was one serious adverse event of pelvic inflammatory disease observed at approximately 12 months after the inhalation of AZD8848. Post dose, there was also a moderate adverse event of dry mouth and dry eyes observed. Both the moderate and serious adverse events were not thought to be causally related to AZD8848 by the Principal Investigator.
